期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Clinicopathological parameters predicting recurrence of pT1N0 esophageal squamous cell carcinoma 被引量:4
1
作者 Li-Yan Xue Xiu-Min Qin +18 位作者 Yong Liu Jun Liang Hua Lin Xue-Min Xue Shuang-Mei Zou Mo-Yan Zhang Bai-Hua Zhang Zhou-Guang Hui Zi-Tong Zhao li-qun ren Yue-Ming Zhang Xiu-Yun Liu Yan-Ling Yuan Jian-Ming Ying Shu-Geng Gao Yong-Mei Song Gui-Qi Wang Sanford M Dawsey Ning Lu 《World Journal of Gastroenterology》 SCIE CAS 2018年第45期5154-5166,共13页
AIM To identify the clinicopathological characteristics of pT1 N0 esophageal squamous cell carcinoma(ESCC) that are associated with tumor recurrence. METHODS We reviewed 216 pT1 N0 thoracic ESCC cases who underwent es... AIM To identify the clinicopathological characteristics of pT1 N0 esophageal squamous cell carcinoma(ESCC) that are associated with tumor recurrence. METHODS We reviewed 216 pT1 N0 thoracic ESCC cases who underwent esophagectomy and thoracoabdominal two-field lymphadenectomy without preoperative chemoradiotherapy. After excluding those cases with clinical follow-up recorded fewer than 3 mo and those who died within 3 mo of surgery, we included 199 cases in the current analysis. Overall survival and recurrencefree survival were assessed by the Kaplan-Meier method, and clinicopathological characteristics associated with any recurrence or distant recurrence were evaluated using univariate and multivariate Cox proportional hazards models. Early recurrence(≤ 24 mo) and correlated parameters were assessed using univariate and multivariate logistic regression models.RESULTS Forty-seven(24%) patients had a recurrence at 3 to 178(median, 33) mo. The 5-year recurrence-free survival rate was 80.7%. None of 13 asymptomatic cases had a recurrence. Preoperative clinical symptoms, upper thoracic location, ulcerative or intraluminal mass macroscopic tumor type, tumor invasion depth level, basaloid histology, angiolymphatic invasion, tumor thickness, submucosal invasion thickness, diameter of the largest single tongue of invasion, and complete negative aberrant p53 expression were significantly related to tumor recurrence and/or recurrence-free survival. Upper thoracic tumor location, angiolymphatic invasion, and submucosal invasion thickness were independent predictors of tumor recurrence(Hazard ratios = 3.26, 3.42, and 2.06, P < 0.001, P < 0.001, and P = 0.002, respectively), and a nomogram for predicting recurrence-free survival with these three predictors was constructed. Upper thoracic tumor location and angiolymphatic invasion were independent predictors of distant recurrence. Upper thoracic tumor location, angiolymphatic invasion, submucosal invasion thickness, and diameter of the largest single tongue of invasion were independent predictors of early recurrence.CONCLUSION These results should be useful for designing optimal individual follow-up and therapy for patients with T1 N0 ESCC. 展开更多
关键词 ESOPHAGEAL SQUAMOUS cell carcinoma Tumor RECURRENCE LYMPH node negative ESOPHAGEAL cancer Recurrence-free survival CLINICOPATHOLOGICAL parameters
下载PDF
联合使用IFN-α和TT-1通过增强NKG2D和MICA的相互作用达到抗肝癌效果的研究(英文)
2
作者 Lan-lan WAN Da-qi ZHANG +1 位作者 Jin-nan ZHANG li-qun ren 《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 SCIE CAS CSCD 2017年第6期522-531,共10页
目的:评估干扰素α(IFN-α)和TT-1(一种蜂毒肽的类似物)联合用药的抗肿瘤效果,并初步研究联合用药的抗肿瘤及免疫调节机制。创新点:为了增强蜂毒肽的抗肿瘤效果,本课题组在其基础上进行改造,合成了一种新的化合物TT-1。该研究第一次将... 目的:评估干扰素α(IFN-α)和TT-1(一种蜂毒肽的类似物)联合用药的抗肿瘤效果,并初步研究联合用药的抗肿瘤及免疫调节机制。创新点:为了增强蜂毒肽的抗肿瘤效果,本课题组在其基础上进行改造,合成了一种新的化合物TT-1。该研究第一次将蜂毒肽类似物和免疫细胞因子IFN-α联合使用,并通过实验证实联合用药可以通过激活免疫调节来增强TT-1的抗肿瘤效果。方法:首先通过MTT实验验证TT-1对HepG-2/Huh7细胞的增殖抑制作用。接着建立HepG-2/Huh7小鼠移植瘤模型,考察TT-1+IFN-α的体内抗肿瘤效果;使用anti-asialo GM-1抗体消除自然杀伤(NK)细胞,验证NK细胞在联合用药中的关键作用。使用流式细胞术和酶联免疫吸附法(ELISA)验证TT-1对HepG-2/Huh7细胞MHC I链相关分子A(MICA)表达的影响,并用实时聚合酶联反应(RT-PCR)和蛋白质印迹(Western blot)对其机制进行探究;通过细胞毒性实验考察TT-1+IFN-α是否可以增强NK细胞对HepG-2/Huh7细胞的特异性杀伤作用。最后使用免疫组化的方法考察TT-1+IFN-α联合用药对肿瘤组织中MICA和NKG2D的表达量的影响。结论:MTT实验表明TT-1可以在体外有效地抑制HepG-2/Huh7细胞的增殖。小鼠移植瘤模型实验结果显示TT-1+IFN-α联合用药比TT-1单独给药更能有效地抑制HepG-2/Huh7移植瘤的生长,但是在消除NK细胞之后该效应明显减弱,说明TT-1+IFN-α的抗肿瘤效应是通过NK细胞特异性介导的。TT-1不仅可以上调肿瘤细胞表面MICA的表达量,而且可以减少可溶性MICA的分泌;进一步研究表明,TT-1通过抑制去整合素金属蛋白酶10(ADAM 10)的表达来阻止MICA从肿瘤细胞表面脱落。细胞毒性实验表明,TT-1+IFN-α可以显著增强NK细胞对HepG-2/Huh7细胞的杀伤作用。免疫组化实验结果显示,TT-1+IFN-α联合用药可以明显增加肿瘤组织中肿瘤细胞表面MICA和NK细胞NKG2D的表达量。综上所述,TT-1+IFN-α联合用药可以通过增强MICA和NKG2D的相互作用达到显著的抗肿瘤效果。 展开更多
关键词 TT-1 干扰素Α 自然杀伤细胞 肝癌 免疫治疗
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部